TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
May 30, 2024
By
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
May 29, 2024
By
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024
By
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
May 9, 2024
By
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
April 24, 2024
By
TScan Therapeutics Announces Exercise of Underwriters’ Option to Purchase Additional Shares
April 24, 2024
By
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
April 22, 2024
By
TScan Therapeutics Announces Closing of Upsized Public Offering
April 19, 2024
By
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
April 17, 2024
By
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
April 16, 2024
By